drugset / Trial / NCT05966324

Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population

NCT05966324

Phase 1 Completed 41 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to compare the characteristics of baxdrostat (CIN-107) in terms of baxdrostat levels over time in the blood in healthy Japanese and Caucasian volunteer participants.

Timeline

Start
2022-07-05
Primary completion
2022-09-20
Completion
2022-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Baxdrostat Small molecule 1 mg Oral
Subject Baxdrostat Small molecule 3 mg Oral
Subject Baxdrostat Small molecule 10 mg Oral

Indications